COMPOSITIONS AND USES FOR TREATING PROGRESSIVE MYOCARDIAL INJURY DUE TO A VASCULAR INSUFFICIENCY

(19)

(11)

EP 2 491 114 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	25.01.2017 Bulletin 2017/04

(45)	Mention of the grant of the patent:
	23.11.2016 Bulletin 2016/47

(21)	Application number: 10825743.7

(22)	Date of filing: 22.10.2010

(51)

International Patent Classification (IPC):

C12N 5/00^(2006.01)
A61K 38/18^(2006.01)
A61P 9/10^(2006.01)

A61K 35/28^(2015.01)
C12N 5/0789^(2010.01)

(86)	International application number:
	PCT/US2010/053744

(87)	International publication number:
	WO 2011/050266 (28.04.2011 Gazette 2011/17)

(54)

COMPOSITIONS AND USES FOR TREATING PROGRESSIVE MYOCARDIAL INJURY DUE TO A VASCULAR INSUFFICIENCY

ZUSAMMENSETZUNGEN UND VERWENDUNGEN ZUR BEHANDLUNG FORTSCHREITENDER MYOKARDIALVERLETZUNGEN AUFGRUND VON GEFÄSSINSUFFIZIENZ

COMPOSITIONS ET UTILISATIONS DANS LE TRAITEMENT D'UNE LÉSION MYOCARDIQUE ÉVOLUTIVE DUE À UNE INSUFFISANCE VASCULAIRE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

23.10.2009 US 254539 P

(43)	Date of publication of application:
	29.08.2012 Bulletin 2012/35

(60)	Divisional application:
	16198257.4

(73)	Proprietor: Amorcyte, Inc.
	Hackensack, NJ 07601 (US)

(72)	Inventors:
	PECORA, Andrew, L. Wyckoff, NJ 07481 (US) PRETI, Robert, A. Ridgefield, CT 06877 (US)

(74)	Representative: Wright, Simon Mark
	J A Kemp 14 South Square Gray's Inn London WC1R 5JJ London WC1R 5JJ (GB)

(56)

References cited: :

US-A1- 2006 019 888
US-A1- 2007 105 217
US-A1- 2007 190 127
US-A1- 2007 275 362

US-A1- 2007 105 217
US-A1- 2007 190 127
US-A1- 2007 275 362
US-A1- 2010 143 317

AIUTI ALESSANDRO ET AL: "Human CD34+ cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 94, no. 1, 1 July 1999 (1999-07-01), pages 62-73, XP002520079, ISSN: 0006-4971
KOLLET O ET AL: "Human CD34+CXCR4- sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 100, no. 8, 15 October 2002 (2002-10-15), pages 2778-2786, XP002324815, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2002-02-0564
A. KAWAMOTO ET AL: "CD34-Positive Cells Exhibit Increased Potency and Safety for Therapeutic Neovascularization After Myocardial Infarction Compared With Total Mononuclear Cells", CIRCULATION, vol. 114, no. 20, 14 November 2006 (2006-11-14), pages 2163-2169, XP055020354, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.106.644518
YEH E T H ET AL: "Transdifferentiation of Human Peripheral Blood CD34<+>-Enriched Cell Population Into Cardiomyocytes, Endothelial Cells, and Smooth Muscle Cells In Vivo", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 108, no. 17, 28 October 2003 (2003-10-28), pages 2070-2073, XP002433317, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000099501.52718.70
W. WOJAKOWSKI: "Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ Stem Cells, and Mononuclear Cells Expressing Early Cardiac, Muscle, and Endothelial Markers Into Peripheral Blood in Patients With Acute Myocardial Infarction", CIRCULATION, vol. 110, no. 20, 16 November 2004 (2004-11-16), pages 3213-3220, XP055009629, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000147609.39780.02
ZHANG ET AL: "Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, ACADEMIC PRESS, GB, vol. 44, no. 2, 16 January 2008 (2008-01-16), pages 281-292, XP022481145, ISSN: 0022-2828
YAMAGUCHI J-I ET AL: "Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 107, no. 9, 11 March 2003 (2003-03-11), pages 1322-1328, XP002305134, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000055313.77510.22
LIU X ET AL: "Neuregulin-1/erbB-Activation Improves Cardiac Function and Survival in Models of Ischemic, Dilated, and Viral Cardiomyopathy", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 48, no. 7, 3 October 2006 (2006-10-03), pages 1438-1447, XP028006726, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2006.05.057 [retrieved on 2006-10-03]
HILL J M ET AL: "Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 348, no. 7, 1 February 2003 (2003-02-01), pages 593-600, XP002980439, ISSN: 0028-4793, DOI: 10.1056/NEJMOA022287
VASA M ET AL: "Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk Factors for Coronary Artery Disease", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 89, no. 1, 6 July 2001 (2001-07-06), pages E1-E7, XP002980437, ISSN: 0009-7330
VASA M ET AL: "Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 89, no. 1, 6 July 2001 (2001-07-06), pages E1-E7, XP002313345, ISSN: 0009-7330
"Chapter 22" In: Braunwald: "Heart diseases 8th edition", 1 January 2008 (2008-01-01), Saunders Elsevier, Philadelphia pages 541-560,


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).